WVE Overview
Upcoming Projects (WVE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (WVE)
-
A Second View: Examining novel candidates for alpha-1 antitrypsin deficiency, including Beam Therapeutics’ BEAM-302 and Wave Life Sciences’ WVE-006
Tickers: WVE, BEAM
Executed On: Jan 22, 2026 at 09:00 AM EST -
Examining novel candidates for alpha-1 antitrypsin deficiency, including Beam Therapeutics’ BEAM-302 and Wave Life Sciences’ WVE-006
Tickers: WVE, BEAM
Executed On: Jan 20, 2026 at 01:30 PM EST -
A look at Arrowhead Pharmaceuticals’ and Wave LifeSciences interim clinical data for their RNA-based obesity programs, including ARO-INHBE / ARO-ALK7 and WVE-007
Tickers: ARWR, WVE
Executed On: Jan 12, 2026 at 11:00 AM EST -
Delving into the Phase 1 INLIGHT Trial data on Wave's siRNA therapy, WVE-007, in patients with obesity
Tickers: WVE, LLY, NVO
Executed On: Dec 23, 2025 at 10:00 AM EST -
Two Week Delay: Survey on Huntington's Disease January 2025
Tickers: QURE, PTCT, WVE
Executed On: Feb 14, 2025 at 12:20 PM EST -
Reviewing the recent Duchenne Muscular Dystrophy Data from Wave Life Sciences on their exon 53 skipper, WVE-N531
Tickers: WVE, SRPT, RNA, NS Pharma
Executed On: Sep 26, 2024 at 11:00 AM EDT
Upcoming & Overdue Catalysts (WVE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (WVE)
-
Phase 1b/2a top line data of Wave Life Science(WVE) WVE-120102 (PRECISION-HD2) in mutant huntingtin (mHTT) 32 mg data due 1Q 2021
Ticker: WVE
Occurred on: Mar 29, 2021 -
Wave Life Sciences(WVE) Receives Fast Track Designation from FDA for Suvodirsen
Ticker: WVE
Occurred on: Sep 16, 2019 -
WAVE Life Sciences Receives Orphan Drug Designation from FDA for its Lead Candidate Designed to Treat Huntington’s Disease
Ticker: WVE
Occurred on: Jun 21, 2016
Strategic Initiatives (WVE)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
